Creating the Next Generation of Targeted Cancer Therapies

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.

A Multi-Asset Product Portfolio of Chemotherapeutics

We employ a drug discovery and development approach that allows us to efficiently design and develop drug candidates rapidly. In just a couple of years, we have successfully advanced our lead PDC, iopofosine into multiple clinical studies in many cancers including a pivotal study for Waldenstrom’s macroglobulinemia. Additionally, we have rapidly progressing proprietary preclinical programs utilizing different payloads and have established several strategic collaborations.

Explore Our Pipeline

Advancing Innovation in Targeted Therapies

Drug conjugate approaches have faced many challenges, including limited to no improvement in toxicities and clinical efficacy. These issues can often be traced back to the mechanism used to target the tumor cells. Understanding this challenge, Cellectar has taken a novel approach to pursue a means of targeting cancers in a manner that takes advantage of the increased metabolic needs of all cancers and allows our compounds to gain entry directly into the tumor cell’s cytoplasm. In order to satisfy its increased metabolism, tumor cells change regions on the cell surface; these changes in the cell surface are what our PLEs target. These changes are unique to tumor cells and do not occur in highly metabolic normal cells. Importantly, because nearly all tumor cells and all tumor types have increased metabolic needs, our molecules can target the primary tumor, any metastatic tissue and the cancer stem cells regardless of the tumor type or location.

View Our Technology

QUESTIONS?

Contact Us

Upcoming Events

66th American Society of Hematology Annual Meeting and Exposition

View All Events

Latest Presentation

Corporate Presentation - November 2024
November 1, 2024
Download now

Leadership

"A commitment to the personal growth and professional development of our employees is the foundation of our high-performance company."

– Jim Caruso
President and CEO

View Leadership

IR Contact Information

Company Information

Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
info@cellectar.com

Investor Relations

Investor Contact
investors@cellectar.com

Business Development

Contact Information
businessdevelopment@cellectar.com

Social Media

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.